| 查看: 163 | 回复: 0 | |||
ienjoysun银虫 (著名写手)
|
[交流]
Novartis in talks to buy Gamida Cell for up to $600 million: report
|
|
Novartis in talks to buy Gamida Cell for up to $600 million: report (Ref: Globes, Jewish Business News, Fidelity) March 18th, 2014 By: Matthew Dennis Tags: Top Story StemEx Clal Biotechnology Gamida Cell Novartis Corporate Affairs Mergers & Acquisitions According to sources close to the matter, Novartis is in advanced discussions to buy Gamida Cell for as much as $600 million, Globes reported Tuesday. Elbit Medical Technologies, which has a 30.8-percent stake in Gamida, confirmed an offer from an unnamed company, noting that it includes a "significant immediate payment and additional future payments totalling hundreds of millions of dollars." Clal Biotechnology, which holds around 22 percent of Gamida, added that the bid was received on March 7. Gamida is developing stem cell therapies for a variety of conditions, including its StemEx treatment, which is being evaluated as part of a transplant regimen for patients with high-risk leukaemia and lymphoma. According to Elbit and Clal, future payments under the deal would depend on meeting development, registration and sales milestones. Globes noted that although talks with Novartis are at an advanced stage, Gamida has not abandoned plans for an initial public offering. The newspaper said that the valuation for the IPO is lower than the potential value of an acquisition, which would likely be the preferred option. http://www.firstwordpharma.com/node/1196136#axzz2wOds3Uam |
回复此楼» 猜你喜欢
TCE药物治疗肿瘤病人后免疫细胞重建的检测
已经有18人回复
-
是不是现在考博都是推荐制？或者是已经内定了？还有通过考试招博士的学校吗？
已经有39人回复
-
药物学论文润色/翻译怎么收费?
已经有227人回复
-
农产品中农药监测的免疫传感器的疑问
已经有0人回复
-
纳米传感器监测农药残留的疑惑
已经有0人回复
-
谁有人卫版 《毒理学基础》第七版书籍
已经有0人回复
-
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
26考博申请 学or专
已经有15人回复
-
小分子化学药物研究中PDE怎么查，有无相应网站推荐？
已经有0人回复
-
他汀类药物对HMG-COA还原酶抑制研究
已经有0人回复